Literature DB >> 9282787

Generation of an infectious cDNA of a highly cardiovirulent coxsackievirus B3(CVB3m) and comparison to other infectious CVB3 cDNAs.

C Lee1, E Maull, N Chapman, S Tracy, J Wood, C Gauntt.   

Abstract

An infectious cDNA of a highly myocarditic coxsackievirus B3 (CVB3m; Nancy strain) was cloned. Sequence data revealed 43 extra non-viral nucleotides upstream of the initial 5' sequence. However, the authentic 5' end sequence was maintained during replication of viral RNA transfected into HeLa cells, suggesting the RNA synthesizing complex edits the picornaviral 5' terminus sequence. Nucleotide sequences of the 5' nontranslated region and the capsid protein gene sequence of CVB3m were compared with the published sequences of five other CVB3 Nancy strains and two main lineages were found. In comparative assays for cardiovirulence, three of four CVB3 tested were cardiovirulent in adolescent male CD-1 mice. Only one of the three available CVB3 strains was neutralized with several anti-CVB3m monoclonal antibodies, suggesting that mutations in the surface epitopes of the capsid polypeptides contribute to antigenic drift within the serotype, perhaps in part through immunoselective pressures. Thus, phenotypic diversity of CVB3 within the prototype Nancy strain is an example of RNA viruses adapting to changing environments (cells, mice and humans) through mutations and selective pressure.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9282787     DOI: 10.1016/s0168-1702(97)00059-2

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  9 in total

1.  Toward testing the hypothesis that group B coxsackieviruses (CVB) trigger insulin-dependent diabetes: inoculating nonobese diabetic mice with CVB markedly lowers diabetes incidence.

Authors:  S Tracy; K M Drescher; N M Chapman; K-S Kim; S D Carson; S Pirruccello; P H Lane; J R Romero; J S Leser
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  Genomic determinants of cardiovirulence in coxsackievirus B3 clinical isolates: localization to the 5' nontranslated region.

Authors:  J J Dunn; N M Chapman; S Tracy; J R Romero
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Expression of an antigenic adenovirus epitope in a group B coxsackievirus.

Authors:  K Höfling; S Tracy; N Chapman; K S Kim; J Smith Leser
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 4.  Multivalent and Multipathogen Viral Vector Vaccines.

Authors:  Katharina B Lauer; Ray Borrow; Thomas J Blanchard
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

5.  A group B coxsackievirus/poliovirus 5' nontranslated region chimera can act as an attenuated vaccine strain in mice.

Authors:  N M Chapman; A Ragland; J S Leser; K Höfling; S Willian; B L Semler; S Tracy
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

6.  Autoimmune myocarditis, valvulitis, and cardiomyopathy.

Authors:  Jennifer M Myers; DeLisa Fairweather; Sally A Huber; Madeleine W Cunningham
Journal:  Curr Protoc Immunol       Date:  2013

7.  The whole genome sequence of coxsackievirus B3 MKP strain leading to myocarditis and its molecular phylogenetic analysis.

Authors:  Bin Liu; Zhe Li; Fengyang Xiang; Fan Li; Yang Zheng; Guoqing Wang
Journal:  Virol J       Date:  2014-02-21       Impact factor: 4.099

8.  Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines.

Authors:  Yanzhen Lin; Wei Wang; Junkai Wan; Ying Yang; Wenkun Fu; Dequan Pan; Linli Cai; Tong Cheng; Xiumin Huang; Yifeng Wang
Journal:  Virol J       Date:  2018-04-10       Impact factor: 4.099

Review 9.  Toll-Like Receptors: Are They Taking a Toll on the Heart in Viral Myocarditis?

Authors:  Kasper Favere; Matthias Bosman; Karin Klingel; Stephane Heymans; Sophie Van Linthout; Peter L Delputte; Johan De Sutter; Hein Heidbuchel; Pieter-Jan Guns
Journal:  Viruses       Date:  2021-05-27       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.